A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures
Clinical trial NCT01713946 · COMPLETED
Trial details
- NCT number
- NCT01713946
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-04-29
- Primary completion
- 2017-10-25
- Enrollment
- 366
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.